Prolaris is a genomic test developed to aid healthcare professionals in predicting prostate cancer aggressiveness in conjunction with clinical parameters such as Gleason score and PSA.
Prolaris is the first test to offer a direct measure of the molecular biology of an individual patient’s prostate cancer. By measuring the expression levels of genes involved in cancer cell proliferation, Prolaris is able to more accurately predict disease aggressiveness.
Prolaris has been shown to be the single most clinically significant prognostic parameter of outcomes at the time of diagnosis. The test provides unique additional information that can be combined with standard clinical factors to make the most accurate prediction of a patient’s prostate cancer aggressiveness Prolaris has been extensively validated across multiple patient cohorts in both pre- and post-treatment scenarios.
Prolaris is a risk stratification tool, designed to measure the aggressiveness of a patient’s cancer to better predict that individual’s risk of disease progression within ten years. It can enable healthcare professionals to better define a treatment/monitoring strategy for their patients.
In the treatment of prostate cancer, Prolaris is prognostic at the point of diagnosis and in the post-surgery setting: At diagnosis, Prolaris can help to identify patients with less aggressive cancer who may be candidates for active surveillance. In addition, Prolaris can identify patients who appear to be clinically low risk, but have a more aggressive disease that requires more extensive treatment.
Prolaris testing is well suited for use in post-prostatectomy patients who have higher risk features after surgery to better estimate their risk of disease recurrence (biochemical recurrence, or BCR) and therefore adjust the level of monitoring or add additional therapy.